Status | Study |
Not yet recruiting |
Study Name: MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Condition: Hypercalcemia Plasmacytoma Re Date: 2017-01-25 Interventions: Drug: Carfilzomib Given IV |
Recruiting |
Study Name: Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Condition: Plasmacytoma POEMS Syndrome Date: 2016-09-26 Interventions: Drug: Dexamethasone Given PO |
Recruiting |
Study Name: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Condition: Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia S Date: 2015-09-21 Interventions: Drug: Fludarabine Days -6 thro |
Recruiting |
Study Name: Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Condition: Plasma Cell Leukemia Plasma Cell Myeloma Date: 2015-09-10 Interventions: Drug: Dexamethasone Given PO |
Recruiting |
Study Name: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone Condition: Solitary Osseous Plasmacytoma Date: 2015-08-04 Interventions: Drug: ixazomib oral |
Recruiting |
Study Name: Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Condition: Plasmacytoma Date: 2015-07-28 Interventions: Drug: Lenalidomide Experimenta |
Terminated |
Study Name: CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Condition: Extramedullary Plasmacytoma Date: 2015-01-08 Interventions: Drug: CDD Chemotherapy |
Recruiting |
Study Name: Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy Condition: Carcinoma Date: 2014-11-03 |
Active, not recruiting |
Study Name: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Condition: Multiple Myeloma Date: 2014-05-01 Interventions: Drug: Daratumumab Daratumumab |
Completed |
Study Name: Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Condition: Multiple Myeloma and Malignant Plasma Cell Neoplasms Date: 2013-12-19 Interventions: Radiation: External Beam radiotherapy External Beam radiotherapy |